Recommendations on dose level selection for repeat dose toxicity studies

被引:11
|
作者
Sewell, Fiona [1 ]
Corvaro, Marco [2 ]
Andrus, Amanda [3 ]
Burke, Jonathan [4 ]
Daston, George [5 ]
Delaney, Bryan [6 ]
Domoradzki, Jeanne [7 ]
Forlini, Carole [8 ]
Green, Maia Louise [9 ]
Hofmann, Thomas [10 ]
Jackel, Sven [11 ]
Lee, Moung Sook [12 ]
Temerowski, Michael [13 ]
Whalley, Paul [14 ]
Lewis, Richard [14 ]
机构
[1] Natl Ctr Replacement Refinement & Reduct Anim Res, Gibbs Bldg,215 Euston Rd, London NW1 2BE, England
[2] Corteva Agrisci Italia SRL, Rome, Italy
[3] Dow Chem Co USA, Midland, MI 48674 USA
[4] Reckitt, Kingston Upon Hull, N Humberside, England
[5] Procter & Gamble Co, Cincinnati, OH USA
[6] Firmenich, Plainsboro, NJ USA
[7] Corteva Agrisci, Indianapolis, IN USA
[8] Arkema, Colombes, France
[9] ExxonMobil Biomed Sci Inc, Annandale, NJ USA
[10] BASF SE, Ludwigshafen, Germany
[11] Merck KGaA, Darmstadt, Germany
[12] Clariant, Sulzbach, Germany
[13] Bayer Crop Sci, Mannheim, Germany
[14] Syngenta Ltd, Bracknell, Berks, England
关键词
Dose selection; Toxicokinetics; Exposure; 3Rs; HAZARD ASSESSMENT; SAFETY;
D O I
10.1007/s00204-022-03293-3
中图分类号
R99 [毒物学(毒理学)];
学科分类号
100405 ;
摘要
Prior to registering and marketing any new pharmaceutical, (agro)chemical or food ingredient product manufacturers must, by law, generate data to ensure human safety. Safety testing requirements vary depending on sector, but generally repeat-dose testing in animals form the basis for human health risk assessments. Dose level selection is an important consideration when designing such studies, to ensure that exposure levels that lead to relevant hazards are identified. Advice on dose level selection is provided in test guidelines and allied guidance documents, but it is not well harmonised, particularly for selection of the highest dose tested. This paper further builds on concepts developed in a technical report by the European Centre for Ecotoxicology and Toxicology of Chemicals (ECETOC) which recommends pragmatic approaches to dose selection considering regulatory requirements, animal welfare and state of the art scientific approaches. Industry sectors have differing degrees of freedom to operate regarding dose level selection, depending on the purpose of the studies and the regulatory requirements/legislation, and this is reflected in the overall recommended approaches. An understanding of systemic exposure should be utilised where possible (e.g., through toxicokinetic approaches) and used together with apical endpoints from existing toxicity studies to guide more appropriate dose level selection. The highest dose should be limited to a reasonable level, causing minimal but evident toxicity to the test animals without significantly compromising their well-being. As the science of predictive human exposure further develops and matures, this will provide exciting and novel opportunities for more human-relevant approaches to dose level selection.
引用
收藏
页码:1921 / 1934
页数:14
相关论文
共 50 条
  • [21] Dose selection for prostate cancer patients based on dose comparison and dose response studies
    Hanks, GE
    Hanlon, AL
    Pinover, WH
    Horwitz, EM
    Price, RA
    Schultheiss, T
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2000, 46 (04): : 823 - 832
  • [22] High dose selection in general toxicity studies for drug development: A pharmaceutical industry perspective
    Buckley, Lorrene A.
    Dorato, Michael A.
    REGULATORY TOXICOLOGY AND PHARMACOLOGY, 2009, 54 (03) : 301 - 307
  • [23] Bayesian decision theory for dose escalation in repeat dose healthy volunteer studies.
    Patterson, SD
    Webber, D
    Zariffa, NMD
    Ireson, M
    Francis, S
    Whitehead, J
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1999, 65 (02) : 173 - 173
  • [24] Issues in the design and interpretation of chronic toxicity and carcinogenicity studies in rodents: Approaches to dose selection
    Rhomberg, Lorenz R.
    Baetcke, Karl
    Blancato, Jerry
    Bus, James
    Cohen, Samuel
    Conolly, Rory
    Dixit, Rakesh
    Doe, John
    Ekelman, Karen
    Fenner-Crisp, Penny
    Harvey, Paul
    Hattis, Dale
    Jacobs, Abigail
    Jacobson-Kram, David
    Lewandowski, Tom
    Liteplo, Robert
    Pelkonen, Olavi
    Rice, Jerry
    Somers, Diana
    Turturro, Angelo
    West, Webster
    Olin, Stephen
    CRITICAL REVIEWS IN TOXICOLOGY, 2007, 37 (09) : 729 - 837
  • [25] Extrapolation of Oligonucleotide Dose Levels Used in Nonclinical Toxicity Studies to Selection of Safe Starting Dose Levels in Human Clinical Trials
    Kornbrust, Doug
    NUCLEIC ACID THERAPEUTICS, 2019, 29 (03) : 123 - 125
  • [26] Are Repeat-Dose Toxicity Studies Informative for Safety Assessment of Vaccine Candidates? A Survey of Vaccine Developers
    Rohde, Cynthia M.
    Destexhe, Eric
    van der Laan, Jan Willem
    Gould, Sarah
    Coe, Rachel
    Haenen, Bert
    INTERNATIONAL JOURNAL OF TOXICOLOGY, 2024,
  • [27] Repeat-Dose Toxicity Studies of 3-Bromopyruvate in Rats Following Oral and Intraperitoneal Administration
    Godin, S.
    Engelke, K.
    Geschwind, J. F.
    INTERNATIONAL JOURNAL OF TOXICOLOGY, 2014, 33 (01) : 49 - 50
  • [28] Symp XVc Established and Emerging Noninvasive Techniques for Functional Measurements in Repeat-Dose Toxicity Studies
    Redfern, W. S.
    Ewart, L.
    Lainee, P.
    Robinson, S.
    Valentin, J. -P
    INTERNATIONAL JOURNAL OF TOXICOLOGY, 2011, 30 (01) : 133 - 134
  • [29] Repeat Dose Toxicity Studies of 3-Bromopyruvate in Dogs Following Intrahepatic Artery and Intraperitoneal Infusion
    Godin, C. S.
    Engelke, K. E.
    Geschwind, J. F.
    INTERNATIONAL JOURNAL OF TOXICOLOGY, 2015, 34 (01) : 106 - 107
  • [30] Determination of dose dependence in repeated dose toxicity studies when mid-dose alone is insignificant
    Kobayashi, Katsumi
    Pillai, Kalathil Sadasivan
    Michael, Mathews
    Cherian, Kotturathu Mammen
    Araki, Akihiro
    Hirose, Akihiko
    JOURNAL OF TOXICOLOGICAL SCIENCES, 2012, 37 (02): : 255 - 260